Claims for Patent: 6,673,838

Summary for Patent: 6,673,838

Title:	Succinate salt of O-desmethyl-venlafaxine
Abstract:	A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Inventor(s):	Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH)
Assignee:	Wyeth (Madison, NJ)
Application Number:	10/073,743
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,673,838
Patent Claims:	1. A compound which is O-desmethyl venlafaxine succinate. 2. The compound of claim 1, wherein the compound is a hydrate of O-desmethyl venlafaxine succinate. 3. The compound of claim 2 which is O-desmethyl venlafaxine succinate monohydrate. 4. The compound of claim 1 wherein the salt is crystalline. 5. The compound of claim 4 wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 10.20, 14.91, 20.56, 22.13, 23.71, 24.60, and 25.79. 6. The compound of claim 4 having an endotherm at about 131.degree. C. 7. The compound of claim 4 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 1. 8. The compound of claim 4 wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 13.18, 14.04, 14.35, 14.66, 16.68, 17.67, 19.24, 25.13, and 31.78. 9. The compound of claim 8 wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 10.25, 13.18, 14.04, 14.35, 14.66, 16.68, 17.67, 19.24, 20.38, 20.56, 23.41, 23.78, 24.57, 25.13, 25.80, and 31.78. 10. The compound of claim 4 having an endotherm at about 127.degree. C. 11. The compound of claim 4 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 2. 12. The compound of claim 4 wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 13.74, 22.55, and 32.42. 13. The compound of claim 12 wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 10.36, 13.74, 14.40, 14.68, 14.96, 16.75, 17.48, 17.76, 19.26, 20.42, 20.74, 22.55, 23.58, 23.82, 24.92, 26.00, 31.86, and 32.42. 14. The compound of claim 4 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 3. 15. The compound of claim 4, wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 11.29, 17.22, 19.64, 20.91, 21.61, 28.86, 29.80, 30.60, 36.85, and 37.70. 16. The compound of claim 15, wherein the compound exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2.theta. (.+-.0.2.degree. 2.theta.) at 10.46, 11.29, 13.69, 14.48, 15.17, 16.62, 17.22, 17.61, 19.22, 19.64, 20.91, 21.61, 22.55, 23.84, 24.77, 25.34, 25.92, 26.40, 28.86, 29.80, 30.60, 33.17, 36.85, and 37.70. 17. The compound of claim 4 having an endotherm at 145.degree. C. 18. The compound of claim 4 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 4. 19. The compound of claim 1 wherein the compound is amorphous. 20. The compound of claim 19 having a T.sub.g onset at 18.degree. C. 21. The compound of claim 1 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 5. 22. The compound of claim 1 having a solubility in water of at least 30 mg/ml at about 25.degree. C. 23. A pharmaceutical composition comprising O-desmethyl venlafaxine succinate and a pharmaceutically acceptable carrier or excipient. 24. The pharmaceutical composition of claim 23 further comprising venlafaxine. 25. A pharmaceutical dosage form comprising a therapeutically effective amount of O-desmethyl venlafaxine succinate and a pharmaceutically acceptable carrier or excipient. 26. An oral dosage form comprising a therapeutically effective amount of O-desmethyl venlafaxine succinate and a pharmaceutically acceptable carrier or excipient. 27. The oral dosage form of claim 26, wherein the dosage form is a tablet or capsule. 28. The oral dosage form of claim 26, wherein the oral dosage form is a sustained release formulation. 29. The oral dosage form of claim 26, further comprising a rate controlling polymer material. 30. The oral dosage form of claim 29, wherein the rate controlling polymer material is selected from hydroxyalkyl celluloses, poly(ethylene) oxides, alkyl celluloses, carboxymethyl celluloses, hydrophilic cellulose derivatives, and polyethylene glycol. 31. The oral dosage form of claim 29, wherein the oral dosage form comprises from about 30 to about 50% by weight of O-desmethyl-venlafaxine succinate and from about 40 to about 70% by weight of the rate controlling polymer material, based upon 100% total weight of oral dosage form. 32. The oral dosage form of claim 31, wherein the oral dosage form comprises from about 32 to about 44% by weight of O-desmethyl-venlafaxine succinate and from about 45 to about 66% by weight of the rate controlling polymer material, based upon 100% total weight of oral dosage form. 33. The oral dosage form of claim 26, wherein the oral dosage form further comprises a binder. 34. The oral dosage form of claim 33, wherein the binder is microcrystalline cellulose. 35. A method of treating a patient suffering from depression comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 36. A method of treating a patient suffering from anxiety comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 37. A method of treating a patient suffering from panic disorder comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 38. A method of treating a patient suffering from generalized anxiety disorder comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 39. A method of treating a patient suffering from post traumatic stress disorder comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 40. A method of treating a patient suffering from premenstrual dysphoric disorder comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 41. A method of treating a patient suffering from a condition selected from fibromyalgia, agorophobia, attention deficit disorder, obsessive compulsory disorder, social anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, chronic fatigue syndrome, urinary incontinence, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's disease, and epilepsy comprising providing to a patient in need thereof an effective amount of O-desmethylvenlafaxine succinate. 42. A method of enhancing cognition or treating cognitive impairment in a patient comprising providing to a patient in need thereof an effective amount of O-desmethyl-venlafaxine succinate. 43. A method for cessation of smoking or other tobacco uses in a patient comprising providing to a patient in need thereof an effective amount of O-desmethyl-venlafaxine succinate. 44. A method for treating hypothalamic amenorrhea in a depressed or non-depressed human female comprising providing to a human female in need thereof an effective amount of O-desmethyl-venlafaxine succinate. 45. A method of lowering the incidence of nausea, vomiting, diarrhea, abdominal pain, headache, vaso-vagal malaise, or trismus resulting from the oral administration of O-desmethylvenlafaxine succinate to a patient comprising orally administering to a patient in need thereof a therapeutically effective amount of a sustained release formulation of O-desmethyl-venlafaxine succinate having a blood plasma level of no more than about 225 ng/ml. 46. A sustained release formulation comprising O-desmethyl-venlafaxine succinate and a pharmaceutically acceptable carrier or excipient, wherein the sustained release formulation provides peak serum levels of up to about 225 ng/ml.